JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203047200 on May 21, 2002

J. Biol. Chem., Vol. 277, Issue 33, 29455-29459, August 16, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/33/29455    most recent
M203047200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hellberg, A.
Right arrow Articles by Olsson, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hellberg, A.
Right arrow Articles by Olsson, M. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Basis of the Globoside-deficient Pk Blood Group Phenotype

IDENTIFICATION OF FOUR INACTIVATING MUTATIONS IN THE UDP-N-ACETYLGALACTOSAMINE: GLOBOTRIAOSYLCERAMIDE 3-beta -N-ACETYLGALACTOSAMINYLTRANSFERASE GENE*

Åsa HellbergDagger , Joyce Poole§, and Martin L. OlssonDagger

From the Dagger  Department of Transfusion Medicine, Institute of Laboratory Medicine, Lund University and Blood Centre, University Hospital, SE-22185 Lund, Sweden and the § International Blood Group Reference Laboratory, BS105ND Bristol, United Kingdom

Received for publication, March 29, 2002, and in revised form, April 29, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The biochemistry and molecular genetics underlying the related carbohydrate blood group antigens P, Pk, and LKE in the GLOB collection and P1 in the P blood group system are complex and not fully understood. Individuals with the rare but clinically important erythrocyte phenotypes P1k and P2k lack the capability to synthesize P antigen identified as globoside, the cellular receptor for Parvo-B19 virus and some P-fimbriated Escherichia coli. As in the ABO system, naturally occurring antibodies, anti-P of the IgM and IgG class with hemolytic and cytotoxic capacity, are formed. To define the molecular basis of the Pk phenotype we analyzed the full coding region of a candidate gene reported in 1998 as a member of the 3-beta -galactosyltransferase family but later shown to possess UDP-N-acetylgalactosamine:globotriaosylceramide 3-beta -N-acetylgalactosaminyltransferase or globoside synthase activity. Homozygosity for different nonsense mutations (C202 right-arrow T and 538insA) resulting in premature stop codons was found in blood samples from two individuals of the P2k phenotype. Two individuals with P1k and P2k phenotypes were homozygous for missense mutations causing amino acid substitutions (E266A or G271R) in a highly conserved region of the enzymatically active carboxyl-terminal domain in the transferase. We conclude that crucial mutations in the globoside synthase gene cause the Pk phenotype.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Pk blood group phenotype was recognized in 1959 by Matson et al. (1) because of antibodies in the serum of a patient whose erythrocytes were shown to lack an antigen related to but not identical with previously discovered P-related antigens (1). Further studies later showed the P antigen to be globotetraosylceramide (Gb4Cer, globoside, GalNAcbeta 3Galalpha 4Galbeta 4GlcCer),1 the most abundant neutral glycolipid in the erythrocyte membrane (2) as well as in other mesodermally derived tissues (3, 4). Later it was found that human fibroblasts with the Pk phenotype were deficient in beta -N-acetylgalactosaminyltransferase activity (5).

With only few exceptions the molecular basis of the major human blood group antigens have been determined and the genes responsible for erythroid expression of the various phenotypes cloned and characterized. However, the biochemistry and molecular genetics behind the carbohydrate-based P1 antigen in the P blood group system (numerical nomenclature 003001 according to the International Society of Blood Transfusion, ISBT)2 and the P, Pk, and LKE antigens in the GLOB collection (ISBT no. 209001, 209002, and 209003) are complex and not yet fully understood (6).

Fig. 1 shows the biosynthetic route to these glycosphingolipid antigens by the sequential addition of monosaccharide residues to ceramide by different glycosyltransferases (7). The key enzyme for initiation of globo-series glycolipid synthesis, UDP-galactose:lactosylceramide 4-alpha -galactosyltransferase (Gb3Cer/Pk/CD77 synthase, alpha 4Gal-T), was independently cloned by three research teams in the year 2000 (8-10). Mutations in this gene were shown to constitute the molecular basis of the p phenotype in which all antigens of the P blood group system and GLOB collection are lacking on the cell surfaces (8, 11). Attempts to find polymorphisms in the alpha 4Gal-T gene correlating with P1+/P1- status were fruitless, however (8). Therefore, it is still unclear if another gene codes for P1 synthase (also an alpha 4Gal-T) or if other mechanisms exist.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Biosynthetic pathway for globoside and related substances of the P blood group system and GLOB blood group collection.

Recently, the UDP-N-acetylgalactosamine:globotriaosylceramide 3-beta -N-acetylgalactosaminyltransferase (Gb4Cer/globoside synthase, EC 2.4.1.79, beta 3GalNAc-T1) gene and its product was characterized by Okajima et al. (12) using an expression cloning approach (12). Surprisingly enough, it turned out to be identical to a previously cloned gene, initially included in the 3-beta -galactosyltransferase family based on genetic homology (13). Although it resembled other 3-beta -galactosyltransferases no enzymatic activity could be defined in the original study (13).

Cells of the p phenotype, which lack P1/P/Pk antigens; of the P2k phenotype, which lack P1/P antigens; and of the P1k phenotype, which lack the P antigen are of principal interest because of potent naturally occurring antibodies that are regularly present in plasma. As in the ABO blood group system, antibodies of the IgM and IgG class (anti-PP1Pk, anti-P1P or anti-P) are made against the missing blood group antigens. While the frequency of the p phenotype in general has been estimated at 5.8 per million (14) it is considerably higher in certain populations, especially in Northern Sweden (15). The frequency of the Pk phenotype is not known but it is generally accepted to be even rarer than p. The frequencies are possibly slightly higher in Finland and Japan but not as marked as for p in Northern Sweden (16).

There are several reasons for the scientific and medical attention spent investigating patients with these rare phenotypes (17). P-related antibodies are implicated in hemolytic transfusion reactions if random antigen-positive blood is transfused. The P, P1, and Pk antigens are well developed on fetal erythrocytes but in most cases relatively mild hemolytic disease of the newborn because of the anti-PP1Pk or anti-P has been reported (16). Women of the p and Pk phenotypes suffer a higher frequency of spontaneous abortion than normal, a phenomenon that is most likely due to the IgG anti-P component (18). The placenta expresses high levels of P and Pk antigen (as opposed to the early fetus itself) and has been suggested as the prime target for these antibodies (19). Another anti-P-mediated disease usually seen in children following a viral infection is paroxysmal cold hemoglobinuria in which P-positive erythrocytes are lysed by a transient auto-anti-P (20).

Globoside/P antigen has also been identified as a cellular receptor for parvo-B19 virus (21) that causes erythema infectiosum, also known as fifth disease, in children and sometimes is complicated by severe aplastic anemia. Complete viral replication and subsequent cell lysis are limited to early erythroid precursor cells expressing the globoside receptor (22). Individuals lacking the receptor appear to be naturally resistant to this infection (23). Finally, it has also been shown that some P-fimbriated E. coli express globoside-binding molecules (PapF and PapG) at the tips of their pili (24), a finding with possible implications for their uropathogenicity.

Because of the relationship to many human pathogens and diseases the interest in glycolipid-based blood group antigens remains high. In this study we tested the hypothesis that the reported beta 3GalNAc-T1/globoside synthase (12) is indeed the enzyme responsible for synthesis of P blood group antigen. By analyzing the coding DNA sequence of the corresponding gene we show here for the first time that mutations capable of abolishing enzyme function are present in individuals with the Pk phenotype.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Blood Samples-- Four blood samples of the Pk phenotype (one P1k and three P2k) were obtained from the liquid nitrogen in-house collection of test cells at the International Blood Group Reference Laboratory (IBGRL). The phenotype of the cells and presence of anti-P in serum were confirmed by standard serological methods at IBGRL and in two cases also by other reference laboratories. For screening of the detected missense mutations blood samples from apparently healthy random blood donors of mixed European descent were used.

DNA Preparation-- DNA was prepared from EDTA or acid-citrate-dextrose blood at the Blood Centre in Lund by a salting out method modified from Miller et al. (25) and dissolved in H2O at a concentration of 100 ng/µl.

PCR Amplification and DNA Sequencing-- Oligonucleotide primers were synthesized by DNA Technology ApS (Aarhus, Denmark). For each reaction 5 pmol of primers P-(-6)-F and P-1015-R or P-123-F and P-891-R (Table I) were mixed with 100 ng of genomic DNA, 2 nmol of each dNTP, 2% glycerol, 1% cresol red, and 0.5 units of AmpliTaq Gold (PerkinElmer/Roche Molecular Biochemicals) in the buffer supplied. The final reaction volume was 11 µl. Thermocycling was undertaken in a GeneAmp PCR system 2400 (PerkinElmer Cetus). Initial denaturation at 96 °C for 7 min was followed by 35 cycles at 94 °C for 30 s, 64 °C for 30 s, 72 °C for 1 min, and a final extension for 2 min. PCR products were excised from 3% agarose gels (Seakem, FMC Bioproducts, Rockland, ME) stained with ethidium bromide (0.56 mg/liter gel, Sigma Chemicals) and purified using the QiaQuick gel extraction kit (Qiagen GmbH, Hilden, Germany). The Big Dye Terminator Cycle sequencing kit (Applied Biosystems Group) and an ABI PRISM 310 Genetic Analyser (Applied Biosystems Group) were used for direct DNA sequencing according to the manufacturer's instructions. Besides the PCR primers, internal primers (Table I) were used as sequencing primers. To avoid artifacts, sequencing was performed on both strands using independently obtained PCR fragments. Sequence analysis was performed with SeqEd software 1.03 (Applied Biosystems Group).

Sequence-specific Primer PCR (PCR-SSP)-- PCR with allele-specific primers designed to detect the two missense mutations found in the study was performed. For A797 right-arrow C detection 2.5 pmol of primer P-797C-null-F and P-1015-R were used together with 0.5 pmol of internal control primers JK-F3L and JK-R3L, modified from Ref. 26, with PCR conditions as above. For G811 right-arrow A detection 7.5 pmol of primer P-811A-null-F and P-1015-R were used instead.

For confirmation of homozygosity consensus primers P-797A-F and P-811G-F substituted P-797C-null-F and P-811A-null-F at 5 and 10 pmol per reaction, respectively. The annealing temperature for the latter reaction was increased to 65 °C for optimal specificity.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PCR Amplification and DNA Sequencing-- Using the oligonucleotide primers shown in Table I the entire coding region of the beta 3GalNAc-T1 was amplified in one fragment in samples from donors with the phenotype P1k (n = 1, English), P2k (n = 3, Arabian, French, Finnish), or common GLOB collection/P blood group phenotypes (n = 2, Swedish). Sequence analysis of the amplified gene fragments was performed and compared with sequences deposited in GenBankTM: AB050855 (12) and Y15062 (13). The Swedish random donors had beta 3GalNAc-T1 gene sequences identical to the consensus GenBankTM entries. However, in two of the P2k samples homozygosity for two distinct nonsense mutations resulting in premature stop codons were detected. The Finnish sample was homozygous for C202 right-arrow T resulting in an immediate stop codon following residue 67. The Arabian sample was homozygous for a single adenosine insertion at nucleotide (nt) 537-538 (AG right-arrow AAG), here designated 538insA. This insertion causes a frameshift from amino acid 180 and a premature stop at codon 182 (consensus-Arg180-His181-Stop). The remaining two samples were homozygous for two different missense mutations. In the English P1k sample glycine at residue 271 is substituted for arginine because of G811 right-arrow A whereas glutamic acid is changed to alanine at residue 266 because of an A797 right-arrow C substitution in the French P2k sample. DNA sequencing chromatograms visualizing the detected sequences from wild-type and Pk donors are found in Fig. 2. A schematic representation of the open reading frames in the consensus and variant alleles of the beta 3GalNAc-T1 gene is shown in Fig. 3.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Oligonucleotide primers used in this study


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   DNA sequencing chromatograms showing the sequence surrounding the mutations found in each sample. Panel 1, nt 197-205 in the Finnish P2k sample; Panel 2, nt 535-543 in the Arabian P2k and 535-544 in the wild-type sample; Panel 3, nt 807-815 in the English P1k sample; Panel 4, nt 793-801 in the French P2k sample. In each quadrant the upper sequence shows the mutated sample and the lower is the consensus sequence from a wild-type sample. Arrows point to the mutated bases.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Schematic representation of the beta 3GalNAc-T1 coding sequence in wild-type and Pk phenotype donors. The bars show the open reading frames of the gene and the location of different mutations (depicted as thick vertical lines) found in this study. The upper bar represents the full coding sequence of consensus samples. The relative locations of primers used for amplification of DNA fragments for sequence analysis and mutation screening (indicated by Footnotes a and c in Table I) are shown as filled and open arrowheads above the bars, respectively. However, the primer targeted against the 3'-untranslated region of the gene was used for both purposes but is filled.

A comparison of glycosyltransferase genes with significant homology revealed that both of the missense mutations found involve charged versus non-charged residues in a highly conserved region of the carboxyl-terminal globular domain of the transferase (Fig. 4). No other deviations from the beta 3GalNAc-T1 consensus sequence were encountered in any of the analyzed samples. No mRNA studies could be undertaken due to lack of fresh samples.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   Multiple amino acid sequence alignment of homologous glycosyltransferases based on ClustalW plots presented in previously published papers (12, 13, 34, 35). Sequences from the enzymatically active globular domain of the carboxyl-terminal portion in the transferases corresponding to amino acids surrounding the residues mutated in two of the Pk samples are shown. Numbering on the left and right refers to the first and last amino acid shown on each line, respectively. The sequences are from human beta 3GalNAc-T1 (12) originally designated beta 3Gal-T3 (13), human beta 3Gal-T1, 2, and 4 (13), human beta 3Gal-T5 (34), human beta 3GlcNAc-T with poly-N-acetyl-lactosamine synthase activity also predesignated beta 3Gn-T (35), a homologous gene, GT9, which was initially published as beta 3Gn-T (35), and a Drosophila melanogaster gene homologue to the human beta 3Gal-T gene family designated Brainiac (36). The two upper lines show the sequences from the English and French Pk individuals. Hyphens represent sequence identity to beta 3GalNAc-T1. Light gray, dark gray, and black boxes symbolize identity between 4-5, 6-7, or all 8 of the compared sequences, respectively.

Confirmation of Homozygosity-- Because no other polymorphisms were detected in the beta 3GalNAc-T1 gene we ensured that both alleles were amplified for sequence analysis by using two independent PCR primer pairs, P-(-6)-F and P-1015-R or P-123-F and P-891-R. In two of the samples the presence of missense mutations and absence of consensus sequence were confirmed with genomic DNA and sequence-specific primers. Representative electrophoretograms are shown in Fig. 5.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 5.   Representative gel electrophoretograms showing PCR-SSP screening for missense mutations found in the globoside synthase gene of individuals with the Pk phenotype. PCR-SSP products were amplified with the primer combinations described (see "Experimental Procedures" and Table I) and separated on 3% agarose gels. The upper (nt 797) and lower (nt 811) panels show screening with primers amplifying the mutated (left) or consensus (right) sequence. Samples from individuals with the following phenotypes are shown: lane 1, Pk phenotype donor homozygous for the A797 right-arrow C (upper) or G811 right-arrow A (lower) mutations; lane 2, Pk phenotype donor negative for the tested mutation; lanes 3 and 4, random donors of common phenotype; lane 5, H2O contamination control. M is the molecular size marker phi X174RF DNA HaeIII (Invitrogen). Filled and thin arrows indicate the globoside synthase-specific fragments (sizes given in base pairs) and the JK blood group gene-derived control (952 bp) DNA fragments, respectively.

Screening for Missense Mutations by Sequence-specific Primer PCR (PCR-SSP)-- DNA samples of 220 mixed European blood donors were screened for the two missense mutations found during the study to exclude that they constitute common polymorphisms in the gene. Neither mutation was detected in any of the 440 alleles analyzed. Representative results outlining the screening procedure are shown in Fig. 5.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The data presented in this report show that mutations in the recently cloned beta 3GalNAc-T1 gene are associated with the clinically important Pk phenotype in which synthesis of the globoside/P antigen cannot take place. The four samples analyzed were homozygous for rare alleles, which is not unexpected considering the low frequency of this phenotype in all populations. This is most probably due to consanguineous marriages as previously shown in at least 7 of 33 studied propositi of the Pk phenotype (16). As is often the case with rare phenotypes when propositi from different ethnic groups and/or geographic areas are studied the molecular background for the samples in this study was quite heterogeneous. Similar data have been obtained for almost all rare blood group phenotypes with sporadic cases in most populations. Some of these variant phenotypes have a higher frequency in geographically isolated populations. A slightly increased frequency of the Pk phenotype has been noted in Japanese and Finns (16). It is therefore possible that the allele with C202 right-arrow T encountered in the Finnish sample is a founder gene responsible for the Pk phenotype also in other Finnish cases similar to the situation with the rare Jk3 negative blood group phenotype in Finns (27).

In two of the investigated samples nonsense mutations at nt 202 or 538 truncate the protein to 20 and 55% of its native length, respectively, thereby making any retention of enzymic activity impossible because the enzymatically active domain is in the carboxyl-terminal portion. This agrees well with other blood group-related glycosyltransferases that lose activity if severely truncated. For example, the common O allele (O1) in the ABO blood group system has a single guanosine deletion at nt 261 causing a reading frameshift that truncates any translated product at residue 117 (28) leaving no resemblance to A or B transferase after residue 86 (thus 25% of the amino acid sequence remains intact). Other examples are inactive forms of the FUT2 gene product, the 2-alpha -fucosyltransferase of the H blood group system, which are truncated at 55 and 61% of the full reading frame (29).

The other two Pk samples had missense mutations changing amino acids in the functionally active globular domain in the carboxyl-terminal portion of the transferase (30). By comparing the amino acid sequence of homologous genes (Fig. 4) it was shown that the mutated residues are either invariant or highly conserved among the sequences compared, suggesting their importance for the function of beta 3GalNAc-T. Furthermore, they are located in an evolutionarily conserved cluster of amino acids found in glycosyltransferases belonging to different functional families (beta 3Gal-T, beta 3GalNAc-T, and beta 3GlcNAc-T) in humans and also in a Drosophila homologue, suggestive of importance for this region across species boundaries and enzyme specificities. Although not expressed and experimentally proven non-functional by enzyme analysis the data presented make it highly probable that both the E266A change from a large negatively charged to a small hydrophobic residue and the G271R change from a small non-charged to a large positively charged residue causes enough disturbance in this well conserved region to render the protein inactive. Again, analogy can be taken from the ABO system where the full-length O2 protein is rendered non-functional by a G268R change (31, 32) at a conserved residue proposed to be exposed in the substrate-binding pocket of the 3-alpha -galactosyltransferase family (33).

Furthermore, it has been shown unambiguously (14) that the P1 antigen (putative gene located on chromosome 22) is inherited independently from the P antigen (globoside synthase gene located on chromosome 3). Thus, there is no reason to believe that G271R and E266A are specific for the P1k and P2k phenotypes, respectively. The frequency of the P1 antigen among Caucasians is ~75%. Any correlation of G811 right-arrow A (G271R) to P1+ status was effectively ruled out by PCR-SSP screening of the 220 samples, none of which were positive for the mutation while the majority was P1+.

The P antigen may now be extracted from the GLOB collection and promoted to constitute a blood group system of its own according to the inclusion criteria set up by the ISBT working party on terminology for red cell surface antigens. The rule is that a blood group system has to be defined by a single genetic locus or possibly two (or three) closely linked loci so that the antigens included in that system are localized to the same (type of) molecule. Based on the data presented here the P antigen is now tied to a defined genetic locus different from other blood group loci and the molecular basis of the null (P1k and P2k) phenotypes of the system has been identified.

    ACKNOWLEDGEMENT

We thank Dr. Alan Chester at the Blood Centre, Lund, Sweden for careful reading of the manuscript and advice concerning carbohydrate and glycosyltransferase nomenclature.

    FOOTNOTES

* This work was supported in part by the Swedish Research Council, the Medical Faculty at Lund University, the Lund University Hospital Donation Funds, the Claes Högman SAGMAN-stipendium, and Tore Nilson's Fund for Medical Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF494103, AF494104, AF494105, AF494106.

To whom correspondence should be addressed: Blood Centre, University Hospital, SE-221 85, Lund, Sweden. Tel.: 46-46-173210; Fax: 46-46-173226; E-mail: Martin_L.Olsson@transfumed.lu.se.

Published, JBC Papers in Press, May 21, 2002, DOI 10.1074/jbc.M203047200

2 Blood group antigens, phenotypes, and antibodies are designated according to the nomenclature recommended by the ISBT working party on terminology for red cell surface antigens.

    ABBREVIATIONS

The abbreviations used are: Gb4Cer, globotetraosylceramide/globoside/GalNAcbeta 3Galalpha 4Galbeta 4GlcCer; Gb3Cer, globotriaosylceramide, Galalpha 4Galbeta 4GlcCer; alpha 4Gal-T, 4-alpha -galactosyltransferase, Gb3Cer/Pk/CD77 synthase; beta 3GalNAc-T1, 3-beta -N-acetylgalactosaminyltransferase, Gb4Cer/globoside synthase; beta 3Gal-T1 to T5, 3-beta -galactosyltransferase 1 to 5; ISBT, International Society of Blood Transfusion; PCR-SSP, polymerase chain reaction with sequence-specific primers; nt, nucleotide.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Matson, G. A., Swanson, J., Noades, J., Sanger, R., and Race, R. R. (1959) Am. J. Hum. Genet. 11, 26-34[Medline] [Order article via Infotrieve]
2. Naiki, M., and Marcus, D. M. (1974) Biochem. Biophys. Res. Commun. 60, 1105-1111[CrossRef][Medline] [Order article via Infotrieve]
3. Cooling, L. L., Koerner, T. A., and Naides, S. J. (1995) J. Infect. Dis. 172, 1198-1205[Medline] [Order article via Infotrieve]
4. Naiki, M., and Marcus, D. M. (1975) Biochemistry 14, 4837-4841[CrossRef][Medline] [Order article via Infotrieve]
5. Kijimoto-Ochiai, S., Naiki, M., and Makita, A. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5407-5410[Abstract/Free Full Text]
6. Daniels, G. L., Anstee, D. J., Cartron, J. P., Dahr, W., Issitt, P. D., Jorgensen, J., Kornstad, L., Levene, C., Lomas-Francis, C., Lubenko, A., et al.. (1995) Vox Sang. 69, 265-279[Medline] [Order article via Infotrieve]
7. Marcus, D. M. (1989) Immunol. Ser. 43, 701-712[Medline] [Order article via Infotrieve]
8. Steffensen, R., Carlier, K., Wiels, J., Levery, S. B., Stroud, M., Cedergren, B., Nilsson, S. B., Bennett, E. P., Jersild, C., and Clausen, H. (2000) J. Biol. Chem. 275, 16723-16729[Abstract/Free Full Text]
9. Kojima, Y., Fukumoto, S., Furukawa, K., Okajima, T., Wiels, J., Yokoyama, K., Suzuki, Y., Urano, T., Ohta, M., and Furukawa, K. (2000) J. Biol. Chem. 275, 15152-15156[Abstract/Free Full Text]
10. Keusch, J. J., Manzella, S. M., Nyame, K. A., Cummings, R. D., and Baenziger, J. U. (2000) J. Biol. Chem. 275, 25315-25321[Abstract/Free Full Text]
11. Furukawa, K., Iwamura, K., Uchikawa, M., Sojka, B. N., Wiels, J., Okajima, T., Urano, T., and Furukawa, K. (2000) J. Biol. Chem. 275, 37752-37756[Abstract/Free Full Text]
12. Okajima, T., Nakamura, Y., Uchikawa, M., Haslam, D. B., Numata, S. I., Furukawa, K., Urano, T., and Furukawa, K. (2000) J. Biol. Chem. 275, 40498-40503[Abstract/Free Full Text]
13. Amado, M., Almeida, R., Carneiro, F., Levery, S. B., Holmes, E. H., Nomoto, M., Hollingsworth, M. A., Hassan, H., Schwientek, T., Nielsen, P. A., Bennett, E. P., and Clausen, H. (1998) J. Biol. Chem. 273, 12770-12778[Abstract/Free Full Text]
14. Race, R. R., and Sanger, R. (1975) The P Blood Groups, Blood Groups in Man , pp. 139-177, Blackwell Scientific Publications, Oxford, UK
15. Cedergren, B. (1973) Hereditas 73, 27-30[Medline] [Order article via Infotrieve]
16. Daniels, G. (1995) P Blood Groups, Human Blood Groups , pp. 227-256, Blackwell Scientific, Oxford, UK
17. Spitalnik, P. F., and Spitalnik, S. L. (1995) Transfus. Med. Rev. 9, 110-122[CrossRef][Medline] [Order article via Infotrieve]
18. Cantin, G., and Lyonnais, J. (1983) Transfusion 23, 350-351[CrossRef][Medline] [Order article via Infotrieve]
19. Lindstrom, K., Dem Borne, A. E., Breimer, M. E., Cedergren, B., Okubo, Y., Rydberg, L., Teneberg, S., and Samuelsson, B. E. (1992) Glycoconj. J. 9, 325-329[CrossRef][Medline] [Order article via Infotrieve]
20. Heddle, N. M. (1989) Transfus. Med. Rev. 3, 219-229[Medline] [Order article via Infotrieve]
21. Brown, K. E., Anderson, S. M., and Young, N. S. (1993) Science 262, 114-117[Abstract/Free Full Text]
22. Brown, K. E., and Young, N. S. (1995) Blood Rev. 9, 176-182[CrossRef][Medline] [Order article via Infotrieve]
23. Brown, K. E., Hibbs, J. R., Gallinella, G., Anderson, S. M., Lehman, E. D., McCarthy, P., and Young, N. S. (1994) N. Engl. J. Med. 330, 1192-1196[Abstract/Free Full Text]
24. Lindberg, F. P., Lund, B., and Normark, S. (1984) EMBO J. 3, 1167-1173[Medline] [Order article via Infotrieve]
25. Miller, S. A., Dykes, D. D., and Polesky, H. F. (1988) Nucleic Acids Res. 16, 1215[Free Full Text]
26. Olsson, M. L., Irshaid, N. M., Hosseini-Maaf, B., Hellberg, Å., Moulds, M. K., Sareneva, H., and Chester, M. A. (2001) Blood 98, 1585-1593[Abstract/Free Full Text]
27. Irshaid, N. M., Henry, S. M., and Olsson, M. L. (2000) Transfusion 40, 69-74[CrossRef][Medline] [Order article via Infotrieve]
28. Yamamoto, F., Clausen, H., White, T., Marken, J., and Hakomori, S. (1990) Nature 345, 229-233[CrossRef][Medline] [Order article via Infotrieve]
29. Koda, Y., Soejima, M., Liu, Y., and Kimura, H. (1996) Am. J. Hum. Genet. 59, 343-350[Medline] [Order article via Infotrieve]
30. Paulson, J. C., and Colley, K. J. (1989) J. Biol. Chem. 264, 17615-17618[Free Full Text]
31. Yamamoto, F., McNeill, P. D., Yamamoto, M., Hakomori, S., Bromilow, I. M., and Duguid, J. K. (1993) Vox Sang. 64, 175-178[Medline] [Order article via Infotrieve]
32. Yamamoto, F., and McNeill, P. D. (1996) J. Biol. Chem. 271, 10515-10520[Abstract/Free Full Text]
33. Gastinel, L. N., Bignon, C., Misra, A. K., Hindsgaul, O., Shaper, J. H., and Joziasse, D. H. (2001) EMBO J. 20, 638-649[CrossRef][Medline] [Order article via Infotrieve]
34. Isshiki, S., Togayachi, A., Kudo, T., Nishihara, S., Watanabe, M., Kubota, T., Kitajima, M., Shiraishi, N., Sasaki, K., Andoh, T., and Narimatsu, H. (1999) J. Biol. Chem. 274, 12499-12507[Abstract/Free Full Text]
35. Zhou, D., Dinter, A., Gutierrez, G. R., Kamerling, J. P., Vliegenthart, J. F., Berger, E. G., and Hennet, T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 406-411[Abstract/Free Full Text]
36. Yuan, Y. P., Schultz, J., Mlodzik, M., and Bork, P. (1997) Cell 88, 9-11[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H. H. Wandall, J. W. Pedersen, C. Park, S. B. Levery, S. Pizette, S. M. Cohen, T. Schwientek, and H. Clausen
Drosophila egghead Encodes a beta 1,4-Mannosyltransferase Predicted to Form the Immediate Precursor Glycosphingolipid Substrate for brainiac
J. Biol. Chem., January 10, 2003; 278(3): 1411 - 1414.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Schwientek, B. Keck, S. B. Levery, M. A. Jensen, J. W. Pedersen, H. H. Wandall, M. Stroud, S. M. Cohen, M. Amado, and H. Clausen
The Drosophila Gene brainiac Encodes a Glycosyltransferase Putatively Involved in Glycosphingolipid Synthesis
J. Biol. Chem., August 30, 2002; 277(36): 32421 - 32429.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/33/29455    most recent
M203047200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hellberg, A.
Right arrow Articles by Olsson, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hellberg, A.
Right arrow Articles by Olsson, M. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.